GRANITE: Airsupra Effectiveness in the Real World (NCT07141277) | Clinical Trial Compass
CompletedNot Applicable
GRANITE: Airsupra Effectiveness in the Real World
United States4,060 participantsStarted 2025-07-09
Plain-language summary
The GRANITE study aims to evaluate the effectiveness of Airsupra versus albuterol in reducing asthma exacerbation risk in a real-world US population.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with at least one prescription record (based on NDC or healthcare common procedure coding system \[HCPCS\] codes) of Airsupra (for Airsupra arm) or albuterol (for selected albuterol comparator arm) since January 2023
* Patients with an asthma indication (indicated by an ICD-10-CM code J45.xx) within the 12 months prior to the index date identified by at least one of the following Health Plan Employer Data Information Set (HEDIS) criteria:
At least one IP claim with asthma as the principal admission diagnosis, At least one ED/urgent care claim with asthma as the principal diagnosis, At least four outpatient claims with asthma as one of the listed diagnoses AND at least two claims for any asthma medications (including any rescue or maintenance medications) within the 12 months prior to the index date, At least four prescriptions for any asthma medications within the 12 months prior to the index date;
* Patients with at least one prescription record (based on NDC or HCPCS codes) of albuterol within the 12 months prior to the index date
* Patients aged ≥18 years on the index date
* Patients with ≥12 months of continuous insurance enrolment prior to and post index date
Exclusion Criteria:
* Patients with at least one medical claim with an ICD-10 code within the 12 months prior to the index date for the following chronic respiratory conditions or other systematic inflammatory diseases routinely treated with SCS: COPD, cystic fibrosis, pulmonary f…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This GRANITE study was a real-world effectiveness study — not a randomized controlled trial — so how confident can you be that the findings about Airsupra versus albuterol reflect what I might actually experience, given that real-world studies can't control for all the differences between patients?
2The trial tracked severe asthma exacerbations as a key outcome — based on what it found, do you think Airsupra would meaningfully reduce my risk of a severe episode compared to using a standard albuterol rescue inhaler on its own?
3Since this study is now completed and was observational in nature, is there published data from it that you've reviewed, and does it change your thinking about whether Airsupra makes sense as my rescue inhaler?
4The study looked at the real-world characteristics of patients who were already prescribed Airsupra — how similar is my asthma profile to the kinds of patients who were included, and does that affect whether the findings are relevant to me?
5Given that Airsupra combines albuterol with budesonide as a rescue inhaler, would switching to it make sense alongside whatever controller medication I'm currently on, or could there be any overlap or dosing concerns I should know about?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Baseline demographics and clinical characteristics of patients receiving Airsupra and albuterol
Timeframe: Baseline period is 12 months prior to the index date
2
Severe asthma exacerbations
Timeframe: Follow-up period for each patient starts the day after the index date and ends at the earliest date of: end of data period,end of continuous enrolment(after 12 months),switch to albuterol(Airsupra cohort),Airsupra (albuterol cohort),or death.